Aims: Alterations of plasma amyloid-β (Aβ) peptides have been related to a high risk for cognitive impairment and dementia. The present study aimed to measure plasma Aβ peptides (Aβ40, Aβ42) and the Aβ40/Aβ42 ratio in a sample of drug-resistant bipolar depressed patients, as well as to explore the possible correlation between biological parameters and clinical changes along an electroconvulsive therapy (ECT) course. Methods: Aβ40 and Aβ42 were measured by means of an ELISA assay in 25 drug-resistant bipolar depressed patients before (T0) and 1 week after (T1) the end of ECT. The patients were clinically evaluated by means of the Hamilton Rating Scale for Depression, 21-item (HRSD-21), the Mini-Mental State Examination, and the Clinical Global Impressions-Severity of Illness Scale. Results: Plasma Aβ levels and the Aβ40/Aβ42 ratio were similar at T0 and T1. The Aβ40/Aβ42 ratio correlated positively with the HRSD total score at both T0 and T1. At T0, a negative correlation was found between the Aβ40/Aβ42 ratio and the improvement of depressive and cognitive symptoms. Moreover, remitters (n = 9; HRSD ≤10) showed a significantly lower Aβ40/Aβ42 ratio at T0 than nonremitters. Conclusion: The present data suggest that a low Aβ40/Aβ42 ratio might characterize a subgroup of depressed patients who respond to ECT, while higher values of this parameter seem to be typical of more severe cases of patients with cognitive impairment.

Keywords:
Amyloid-β, Depression, Cognitive Impairment, Dementia, Electroconvulsive therapy
1.
Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM: History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008;70:1258-1264.
2.
Gualtieri CT, Johnson LG: Age-related cognitive decline in patients with mood disorders. Progr Neuropsychopharmacol Biol Psychiatry 2008;32:962-967.
3.
Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA: Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69:493-498.
4.
Kessing LV, Andersen PK: Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004;75:1662-1666.
5.
Robinson LJ, Thompson JM, Gallagher P, et al: A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105-115.
6.
Torres IJ, Boudreau VG, Yatham LN: Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand 2007;434(suppl):17-26.
7.
Aznar S, Knudsen GM: Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 2011;23:177-193.
8.
Selkoe DJ: The ups and downs of Abeta. Nat Med 2006;12:758-759.
9.
Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM: The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16:30-39.
10.
van Dijk EJ, Prins ND, Vermeer SE, et al: Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004;55:570-575.
11.
Gurol ME, Irizarry MC, Smith EE, et al: Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-29.
12.
Longstreth WT Jr, Manolio TA, Arnold A, et al: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3,301 elderly people: the Cardiovascular Health Study. Stroke 1996;27:1274-1282.
13.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
14.
de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071-1076.
15.
Van Oijen M, Hofman A, Soares HD, et al: Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case cohort study. Lancet Neurol 2006;5:655-660.
16.
Graff-Radford NR, Crook JE, Lucas J, et al: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354-362.
17.
Xu W, Kawarabayashi T, Matsubara E, et al: Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 2008;1219:169-179.
18.
Qiu WQ, Sun X, Selkoe DJ, et al: Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007;22:536-542.
19.
Sun X, Mwamburi DM, Bungay K, et al: Depression, antidepressants, and plasma amyloid beta (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007;62:1413-1417.
20.
Sun X, Steffens DC, Au R, et al: Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 2008;65:542-550.
21.
Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, Arai H: Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriatrics 2009;9:180-185.
22.
Piccinni A, Origlia N, Veltri A, et al: Plasma β-amyloid peptides levels: a pilot study in bipolar depressed patients. J Affect Disord 2012;138:160-164.
23.
Pagnin D, de Queiroz V, Pini S, Cassano GB: Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20:13-20.
24.
Zomberg GL, Pope HG: Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408.
25.
Daly JJ, Prudic J, Devanand DP, et al: ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001;3:95-104.
26.
Bloch Y, Ratzoni G, Sobol D, Mendlovic S, Gal G, Levkovitz Y: Gender differences in electroconvulsive therapy: a retrospective chart review. J Affect Disord 2005;84:99-102.
27.
Kho KH, Zwinderman AH, Blansjaar BA: Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. J Clin Psychiatry 2005;66:894-899.
28.
Pluijms EM, Birkenhäger TK, Mulder PG, van den Broek WW: Influence of episode duration of major depressive disorder on response to electroconvulsive therapy. J Affect Disord 2006;90:233-237.
29.
Dombrovski AY, Mulsant BH, Haskett RF, Prudic J, Begley AE, Sackeim HA: Predictors of remission after electroconvulsive therapy in unipolar major depression. J Clin Psychiatry 2005;66:1043-1049.
30.
Thase ME, Rush AJ: When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-29.
31.
Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659.
32.
Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
33.
Hamilton MA: Rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
34.
Guy W: ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.
35.
Lecrubier Y: How do you define remission? Acta Psychiatr Scand 2002;415:7-11.
36.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189-198.
37.
Zimmermann R, Schmitt H, Rotter A, Sperling W, Kornhuber J, Lewczuk P: Transient increase of plasma concentrations of amyloid β peptides after electroconvulsive therapy. Brain Stimul 2012;5:25-29.
38.
Pomara N, Doraiswamy PM, Willoughby LM, et al: Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 2006;31:341-349.
39.
Baba H, Nakano Y, Maeshima H, et al: Metabolism of amyloid-β protein may be affected in depression. J Clin Psichiatry 2012;73:115-120.
40.
Pomara N, Murali Doraiswamy P: Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? Med Hypotheses 2003;60:640-643.
41.
Pomara N, Sidtis JJ: Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets. Br J Pharmacol 2010;161:768-770.
42.
Lindefors E, Brodin E, Metsis M: Spatiotemporal selective effects on brain-derived neurotrophic factor and Trk B messenger RNA in rat hippocampus by electroconvulsive shock. Neuroscience 1995;65:661-670.
43.
Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547.
44.
Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA: Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. J ECT 2002;18:138-143.
45.
Piccinni A, Marazziti D, Catena M, et al: Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008;105:279-283.
46.
Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
47.
Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, et al: Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 2006;16:620-624.
48.
Marano CM, Phatak P, Vemulapalli UR, et al: Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 2007;68:512-517.
49.
Taylor SM: Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT 2008;24:160-165.
50.
Okamoto T, Yoshimura R, Ikenouchi-Sugita A, et al: Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1185-1190.
51.
Piccinni A, Del Debbio A, Medda P, et al: Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 2009;19:349-355.
52.
Tong L, Thornton PL, Balazs R, Cotman CW: Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem 2001;276:17301-17306.
53.
Arvanitis DN, Ducatenzeiler A, Ou JN, et al: High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. J Neurochem 2007;103:216-228.
54.
Arancio O, Chao MV: Neurotrophins, synaptic plasticity and dementia. Curr Op Neurobiol 2007;17:325-330.
55.
Arancibia S, Silhol M, Moulière F, et al: Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Disease 2008;31:316-326.
56.
Colaianna M, Tucci P, Zotti M, et al: Soluble beta amyloid(1-42): a critical player in producing behavioral and biochemical changes evoking depressive-related state? Br J Pharmacol 2010;159:1704-1715.
57.
Mehta PD, Pirttila T, Patrick BA, et al: Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001;304:102-106.
58.
Kawarabayashi T, Younkin LH, Saido TC, et al: Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-381.
59.
Giedraitis V, Sundelöf J, Irizarry MC, et al: The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 2007;427:127-131.
60.
Le Bastard N, Aerts L, Leurs J, et al: No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55:820-825.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.